SLC5A2 and type 2 diabetes mellitus: SGLT2-Is are an effective class of agents for the management of hyperglycemia of T2DM, achieving reductions in glycosylated hemoglobin (HbA1c) of 7–10 mmol/mol (0.6–0.9%) when compared with placebo [13].